835 related articles for article (PubMed ID: 26795209)
1. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
2. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
Park W; Yoo DH; Miranda P; Brzosko M; Wiland P; Gutierrez-Ureña S; Mikazane H; Lee YA; Smiyan S; Lim MJ; Kadinov V; Abud-Mendoza C; Kim H; Lee SJ; Bae Y; Kim S; Braun J
Ann Rheum Dis; 2017 Feb; 76(2):346-354. PubMed ID: 27117698
[TBL] [Abstract][Full Text] [Related]
4. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
Park W; Hrycaj P; Jeka S; Kovalenko V; Lysenko G; Miranda P; Mikazane H; Gutierrez-Ureña S; Lim M; Lee YA; Lee SJ; Kim H; Yoo DH; Braun J
Ann Rheum Dis; 2013 Oct; 72(10):1605-12. PubMed ID: 23687259
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
Park W; Lee SJ; Yun J; Yoo DH
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
8. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
Tweehuysen L; van den Bemt BJF; van Ingen IL; de Jong AJL; van der Laan WH; van den Hoogen FHJ; den Broeder AA
Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
[TBL] [Abstract][Full Text] [Related]
10. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
12. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
14. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Yoo DH; Hrycaj P; Miranda P; Ramiterre E; Piotrowski M; Shevchuk S; Kovalenko V; Prodanovic N; Abello-Banfi M; Gutierrez-Ureña S; Morales-Olazabal L; Tee M; Jimenez R; Zamani O; Lee SJ; Kim H; Park W; Müller-Ladner U
Ann Rheum Dis; 2013 Oct; 72(10):1613-20. PubMed ID: 23687260
[TBL] [Abstract][Full Text] [Related]
15. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
Codreanu C; Šírová K; Jarošová K; Batalov A
Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
[TBL] [Abstract][Full Text] [Related]
16. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
17. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
Kim HA; Lee E; Lee SK; Park YB; Shin K
BioDrugs; 2020 Aug; 34(4):529-539. PubMed ID: 32696266
[TBL] [Abstract][Full Text] [Related]
18. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
[TBL] [Abstract][Full Text] [Related]
20. CT-P13: design, development, and place in therapy.
Gabbani T; Deiana S; Annese V
Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]